Amgen Inc. is seeing a notable rise in its stock price amid recent developments in the pharmaceutical sector.
Amgen Inc. (NASDAQ:AMGN) shares are up 1.57%, closing at CA$382.26. This positive movement comes as investors react to recent news about competitor Novartis and its failed cholesterol drug trial, which could impact the broader market.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$203.47B
P/E
23.3x
Div. yield
2.61%
Div. / share
$9.80
52W high
$447.03
52W low
$262.49
1W change
-3.81%
Beta
0.43
Analyst Price Targets
Based on 32 analysts covering AMGN · as of Sep 17, 2026
Wall Street analysts forecast AMGN stock price to rise 1297.3% over the next 12 months.
Consensus
Buy3.63 / 5.00
Avg. Target
C$388.03
+1297.3% Upside
Current Price
C$27.77
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
38.0%
Annualized
90-Day Vol
33.1%
Annualized
Trend (90d)
+40.3%
Annualized drift
90d Mean
C$438.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$398.47 | C$349.55 – C$454.23 |
| 60 trading days | C$418.07 | C$347.38 – C$503.16 |
| 90 trading days | C$438.65 | C$349.61 – C$550.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Amgen's stock performance reflects investor sentiment towards the pharmaceutical sector, especially in light of recent trial results that may shift market dynamics.
Amgen's Market Cap Reaches CA$203.47 Billion
With a market cap of CA$203.47 billion and a P/E ratio of 23.30, Amgen shows solid financial health, making it an attractive option for investors in the biotech sector.
Bull case
Novartis' failed pelacarsen trial opens the door for Amgen's competing Lp(a) drug, olpasiran, to gain market share in the cardiovascular space. With a strong pipeline and solid financials, Amgen is well-positioned to benefit from this setback for its competitors.
Bear case
Despite today's gains, Amgen faces ongoing competition and market pressures that could affect its future growth. Investors should stay cautious as the pharmaceutical landscape evolves and regulatory challenges continue.
Market Reaction to Novartis' Trial Failure
Advertisement
The recent failure of Novartis' pelacarsen in clinical trials has created a more favorable environment for Amgen's olpasiran. Investors are optimistic about Amgen's potential to take advantage of this setback, positioning itself as a leading contender in the Lp(a) treatment market.
Amgen's Financial Strength
With a market cap of CA$203.47 billion and a profit margin of 22.95%, Amgen continues to demonstrate its robust financial health. The company's P/E ratio of 23.30 indicates a solid valuation compared to its peers, making it a compelling choice for investors seeking stability in the biotech sector.
Looking Ahead
As Amgen benefits from today's gains, investors should monitor upcoming developments in the pharmaceutical landscape. With ongoing competition and regulatory challenges, the company must keep innovating and adapting to maintain its growth trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
